We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmacyclics has announced that Cancer Research, the journal of the
American Association for Cancer Research (AACR), published a study that
further characterizes the mechanism of action of Xcytrin injection and provides
better understanding of the drug's unique anticancer properties.
Halozyme Therapeutics has presented results from preclinical studies with the
company's recombinant human PH20 (rHuPH20) hyaluronidase enzyme at the 2005
Association for Research in Vision and Ophthalmology annual meeting.
Myriad Genetics announced that preliminary results of its Phase II clinical
trial of Flurizan did not achieve statistical significance in patients with
mild to moderate Alzheimer's disease; however, a positive trend was observed
on all three primary endpoints in patients with mild Alzheimer's disease, on
the 800 mg twice-daily dose.
Genaera and study investigators announced recently positive interim clinical
trial results, including pharmacokinetic data and visual acuity outcomes, from
a multicenter open-label U.S. Phase II clinical trial.
Abbott has presented the results of its pivotal Phase III clinical studies for
Zemplar capsules in patients with Stage III and IV chronic kidney disease (CKD)
who do not yet require dialysis.
Exelixis has submitted an investigational new drug application to the FDA for
XL844, the sixth compound to advance in clinical development from the company's
internal discovery program within two years.
OSI Pharmaceuticals and Genentech have announced that OSI submitted a supplemental
new drug application with the FDA for use of Tarceva plus gemcitabine chemotherapy
for the treatment of advanced pancreatic cancer in patients who have not received
any previous treatment.
The FDA has accepted for filing and granted priority review of Tercica's new
drug application (NDA) for Increlex, or recombinant human insulin-like growth
factor-1 (rhIGF-1).
Large Scale Biology (LSBC) and Bayer CropScience have entered into a collaborative
R&D agreement to investigate the plant-based expression of lysosomal acid
lipase (LAL), an LSBC-proprietary pharmaceutical product for important orphan
and possibly other diseases.